Sirna Therapeutics announced this week that it has filed an investigational new drug application to begin clinically testing an RNAi-based treatment for age-related macular degeneration, making it the second company to have done so.
Sirna Therapeutics announced this week that it has filed an investigational new drug application to begin clinically testing an RNAi-based treatment for age-related macular degeneration, making it the second company to have done so.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.